SLC6A1 and epilepsy: Although the FDA-approval might expedite the repurposing of 4-PBA, vigilant pediatrician guidance and further research (to determine the proper use and dosage regimen) is advised for its off-label use in CTD and hGAT-1-associated epilepsies in children.